A Phase 3 interventional study of Baloxavir Marboxil and Oseltamivir in Influenza, sponsored by Hoffmann-La Roche. Completed at 37 sites in 7 countries. Open to participants aged 1 Year to 11 Years. Per ClinicalTrials.gov, last updated 2020-04-29.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing baloxavir in Influenza, Human — 7 open to participants now, 7 under way, 5 of them phase 3. baloxavir · Influenza, Human.
Among the 18 studies testing baloxavir in Influenza, Human, this one is the 15th largest by enrollment, is the only one that started in 2018, is one of 12 in phase 3, and was the 4th registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →7 of the 18 studies testing baloxavir in Influenza, Human are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in China
Ages 5+ · Healthy volunteers
Unity Health Toronto · Sites in Canada
Ages 18+
Dre Pauline Vetter · Sites in Switzerland
Ages 18+
Hoffmann-La Roche · Sites in United States, Bulgaria, Poland and 1 more country
Ages 3 wk–11 yrs
University of Oxford · Sites in Brazil, Laos, Nepal and 1 more country
Ages 18–60
By country, each count listing its studies:
baloxavir: first FDA approval 2018 (XOFLUZA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 1 Year to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 13 · Phase 4 3
First in 2016; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 173 is below the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 483 across the 18 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 18 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
22 studies in Influenza, Human by Hoffmann-La Roche: 2 open now, 2 under way, 2 of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 22 studies in Influenza, Human by Hoffmann-La Roche, this one is the 7th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2018, is one of 10 in phase 3, and was the 16th registered.
Hoffmann-La Roche’s Influenza, Human studies by the year they started, since 2006.
5 of the studies testing baloxavir in Influenza, Human that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07314905Phase 3Unity Health TorontoAdaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) | 2027-03-31 |
| NCT06653569Phase 3Dre Pauline VetterEfficacy of Baloxavir Against Influenza in Hospitalized Patients: The INFLUENT Study (INpatients inFLUENza Treatment) | 2027-04 |
| NCT07827599Phase 3Hoffmann-La RocheA Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants | 2027-04-30 |
| NCT06094010Phase 3Hoffmann-La RocheA Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts | 2027-05-11 |
| NCT05648448University of OxfordA Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza | 2027-01-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 18 studies testing baloxavir in Influenza, Human, from their registry updates:
Among Hoffmann-La Roche’s 22 in Influenza, Human:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, pharmacokinetics, and efficacy of baloxavir marboxil compared with oseltamivir in a single influenza episode in otherwise healthy pediatric participants (i.e., 1 to \<12 years of age) with influenza-like symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single oral dose of baloxavir marboxil on Day 1 (based on body weight). Oseltamivir matching placebo will also be administered orally twice daily (BID) for 5 days.
Drug: Baloxavir Marboxil
Participants will receive oseltamivir orally BID for 5 days (based on body weight). Baloxavir marboxil matching placebo will also be administered orally on Day 1
Drug: Oseltamivir
Baloxavir marboxil will be administered as oral suspension in a single dose on Day 1. Oseltamivir matching placebo will also be administered as oral suspension twice daily (BID) for 5 days.
Oseltamivir will be administered as oral suspension BID for 5 days. Participants receiving oseltamivir will also receive baloxavir marboxil matching placebo as oral suspension, single dose on Day 1.
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A serious adverse event (SAE) is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.
Time frame: Up to Day 29
Plasma Concentrations of Baloxavir Marboxil - Sparse PK Population
Results provided by body-weight groups for participants in the Baloxavir Marboxil arm. Values below lower limit of quantification (0.5 ng/mL) are set to zero.
Time frame: Days 1 (Post-Dose), 2, 4, 6 and 10
Plasma Concentrations of S-033447 - Sparse PK Population
Results provided by body-weight groups for participants in the Baloxavir Marboxil arm.
Time frame: Days 1 (Post-Dose), 2, 4, 6 and 10
Plasma Concentrations of Baloxavir Marboxil - Extensive PK Population
Results provided by body-weight groups for participants in the Baloxavir Marboxil arm. Values below lower limit of quantification (0.5 ng/mL) are set to zero.
Time frame: Days 1 (Post-Dose), 2, 4, 6 and 10
Plasma Concentrations of S-033447 - Extensive PK Population
Results provided by body-weight groups for participants in the Baloxavir Marboxil arm. Values below lower limit of quantification (0.5 ng/mL) are set to zero.
Time frame: Days 1 (Post-Dose), 2, 4, 6 and 10
Time to Alleviation of Influenza Signs and Symptoms
Time to alleviation of influenza signs and symptoms is defined as the length of time taken from the start of treatment to the point at which all of the following criteria are met and remain so for at least 21.5 hours: * A score of 0 (no problem) or 1 (minor problem) for cough and nasal symptoms (items 14 and 15 of the Canadian Acute Respiratory Illness and Flu Scale \[CARIFS\]) * A "yes" response to the following question on the CARIFS: "Since the last assessment has the subject been able to return to day care/school, or resume his or her normal daily activity in the same way as performed prior to developing the flu?" * First return to afebrile state (tympanic temperature ≤37.2 degree Celsius \[°C\])
Time frame: Up to Day 15
Duration of Fever
Length of time taken by participants to return to afebrile state \[tympanic temperature ≤ 37.2°C\] and remaining so for at least 21.5 hours.
Time frame: Up to Day 15
Duration of Symptoms
The clinical efficacy of baloxavir marboxil is evaluated by duration of symptoms i.e., alleviation of all symptoms as defined by a score of 0 \[no problem\] or 1 \[minor problem\] and remaining so for at least 21.5 hours, for all 18 symptoms specified in the CARIFS questionnaire.
Time frame: Up to Day 15
Time to Return to Normal Health and Activity
Time to Return to Normal health and activity' is identified by a 'Yes' response to the following question on the CARIFS: "Since the last assessment has the patient been able to return to day care/school, or resume his or her normal daily activity in the same way as performed prior to developing the flu?"
Time frame: Up to Day 15
Frequency of Influenza-Related Complications
Influenza related complications include death, hospitalization, radiologically confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, myositis.
Time frame: Up to Day 29
Percentage of Participants With Influenza-Related Complications
Influenza related complications include death, hospitalization, radiologically confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, myositis.
Time frame: Up to Day 29
Percentage of Participants Requiring Antibiotics
Time frame: Up to Day 29
Time to Cessation of Viral Shedding by Virus Titer
Time to cessation of viral shedding by virus titer is defined as the time, in hours, between the initiation of any study treatment and first time when the influenza virus titer is below the limit of detection.
Time frame: Day 1 - Day 29
Time to Cessation of Viral Shedding by RT-PCR
Time to cessation of viral shedding by RT-PCR, in hours, is defined as the time between the initiation of any study treatment and first time when the virus RNA by RT-PCR is below the limit of detection.
Time frame: Day 1 - Day 29
Change From Baseline in Influenza Virus Titer at Day 2, 4, 6, 10, 15, 29
Influenza virus titer (log10TCID50/ML) is the quantity of influenza virus in a given volume within the samples obtained from nasal swabs. If influenza virus titer was less than the lower limit of quantification, the virus titer was imputed as 0.749 (log10TCID50/mL). A lower value indicates lower viral titer.
Time frame: Baseline, Day 2, 3 (optional), 4, 6, 10, 15 (optional), 29
Change From Baseline in the Amount of Virus RNA (RT-PCR) at Day 2, 4, 6, 10, 15, 29
If the amount of virus RNA was less than the lower limit of quantification, the amount of virus RNA was imputed as 2.18 for flu A and 2.93 for flu B (log10 virus particles/mL)
Time frame: Baseline, Day 2, 3 (optional), 4, 6, 10, 15 (optional), 29
Percentage of Participants With Positive Influenza Virus Titer at Day 2, 4, 6, 10
Time frame: Baseline, Day 2, 3 (optional), 4, 6, 10
Percentage of Participants Positive by RT-PCR at Day 2, 4, 6, 10, 15, 29
Time frame: Day 2, 3 (optional), 4, 6, 10, 15 (optional), 29
Area Under the Curve in Virus Titer
Area under the curve (AUC) in virus titer was calculated using the trapezoidal method.
Time frame: Day 1 - Day 29
Area Under the Curve in the Amount of Virus RNA (RT-PCR)
AUC in virus RNA (RT-PCR) is defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 10. AUC is calculated using the trapezoidal method similar to AUC in virus titer.
Time frame: Day 1 - Day 10
Area Under the Concentration to Time Curve From Time 0 to Infinity (AUC0-inf) of Baloxavir Marboxil
Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.
Time frame: Up to Day 10
Area Under the Concentration to Time Curve From Time 0 to Infinity (AUC0-inf) of S-033447.
Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.
Time frame: Up to Day 10
Maximum Plasma Concentration (Cmax) of Baloxavir Marboxil
Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.
Time frame: Up to Day 10
Maximum Plasma Concentration (Cmax) of S-033447
Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.
Time frame: Up to Day 10
Time to Maximum Plasma Concentration (Tmax) of Baloxavir Marboxil
Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.
Time frame: Up to Day 10
Time to Maximum Plasma Concentration (Tmax) of S-033447
Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.
Time frame: Up to Day 10
Plasma Concentrations of Baloxavir Marboxil by Dosage
Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.
Time frame: 24, 72, 96 and 240 hours post-dose
Plasma Concentrations of S-033447 by Dosage
Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.
Time frame: 24, 72, 96 and 240 hours post-dose
| Milestone | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Started | 115 | 58 |
| Completed | 112 | 57 |
| Not completed | 3 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Physician decision | 1 | 0 |
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A serious adverse event (SAE) is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.
| percentage of participants | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Adverse Events (AEs) | 46.1 | 53.4 |
| Serious Adverse Events (SAEs) | 0 | 0 |
Results provided by body-weight groups for participants in the Baloxavir Marboxil arm. Values below lower limit of quantification (0.5 ng/mL) are set to zero.
| ng/mL | Baloxavir Marboxil |
|---|---|
| 5 - <10 kg (Day 1) | 0.000 ± NA |
| 5 - <10 kg (Day 2) | 0.000 ± NA |
| 5 - <10 kg (Day 6) | 0.000 ± NA |
| 10 - <15 kg (Day 1) | 0.073 ± 0.2001 |
| 10 - <15 kg (Day 2) | 0.000 ± 0.0000 |
| 10 - <15 kg (Day 4) | 0.000 ± 0.0000 |
| 10 - <15 kg (Day 6) | 0.000 ± 0.0000 |
| 10 - <15 kg (Day 10) | 0.000 ± 0.0000 |
| 15 - <20 kg (Day 1) | 0.090 ± 0.2386 |
| 15 - <20 kg (Day 2) | 0.000 ± 0.0000 |
| 15 - <20 kg (Day 4) | 0.000 ± 0.0000 |
| 15 - <20 kg (Day 6) | 0.000 ± 0.0000 |
| 15 - <20 kg (Day 10) | 0.000 ± 0.0000 |
| >=20 kg (Day 1) | 0.048 ± 0.1936 |
| >=20 kg (Day 2) | 0.000 ± 0.0000 |
| >=20 kg (Day 4) | 0.000 ± 0.0000 |
| >=20 kg (Day 6) | 0.000 ± 0.0000 |
| >=20 kg (Day 10) | 0.000 ± 0.0000 |
Results provided by body-weight groups for participants in the Baloxavir Marboxil arm.
| ng/mL | Baloxavir Marboxil |
|---|---|
| 5 - <10 kg (Day 1) | 45.700 ± NA |
| 5 - <10 kg (Day 2) | 45.800 ± NA |
| 5 - <10 kg (Day 6) | 3.110 ± NA |
| 10 - <15 kg (Day 1) | 49.084 ± 53.6689 |
| 10 - <15 kg (Day 2) | 42.900 ± 16.5227 |
| 10 - <15 kg (Day 4) | 9.233 ± 5.3879 |
| 10 - <15 kg (Day 6) | 2.965 ± 1.6480 |
| 10 - <15 kg (Day 10) | 0.367 ± 0.6351 |
| 15 - <20 kg (Day 1) | 64.160 ± 73.6320 |
| 15 - <20 kg (Day 2) | 67.729 ± 46.7346 |
| 15 - <20 kg (Day 4) | 15.840 ± 10.8285 |
| 15 - <20 kg (Day 6) | 4.829 ± 3.6562 |
| 15 - <20 kg (Day 10) | 1.110 ± 1.9226 |
| >=20 kg (Day 1) | 29.899 ± 26.1558 |
| >=20 kg (Day 2) | 56.287 ± 40.4073 |
| >=20 kg (Day 4) | 18.674 ± 11.2179 |
| >=20 kg (Day 6) | 7.397 ± 5.0530 |
| >=20 kg (Day 10) | 3.953 ± 2.2536 |
Results provided by body-weight groups for participants in the Baloxavir Marboxil arm. Values below lower limit of quantification (0.5 ng/mL) are set to zero.
| ng/mL | Baloxavir Marboxil |
|---|---|
| Day 1, 0.5 - 2 hrs (10 - <15 kg) | 0.000 ± 0.0000 |
| Day 1, 4 hrs (10 - <15 kg) | 0.000 ± 0.0000 |
| Day 1, 6 hrs (10 - <15 kg) | 0.000 ± NA |
| Day 2 (10 - <15 kg) | 0.000 ± 0.0000 |
| Day 4 (10 - <15 kg) | 0.000 ± NA |
| Day 6 (10 - <15 kg) | 0.000 ± 0.0000 |
| Day 10 (10 - <15 kg ) | 0.000 ± NA |
| Day 1, 0.5 - 2 hrs (15 - <20 kg) | 0.000 ± 0.0000 |
| Day 1, 4 hrs (15 - <20 kg) | 0.000 ± NA |
| Day 1, 6 hrs (15 - <20 kg) | 0.000 ± NA |
| Day 2 (15 - <20 kg) | 0.000 ± 0.0000 |
| Day 4 (15 - <20 kg) | 0.000 ± NA |
| Day 6 (15 - <20 kg) | 0.000 ± 0.0000 |
| Day 1, 0.5 - 2 hrs (>=20 kg) | 0.051 ± 0.1600 |
| Day 1, 4 hrs (>=20 kg) | 0.062 ± 0.1863 |
| Day 1, 6 hrs ((>=20 kg) | 0.000 ± 0.0000 |
| Day 2 (>=20 kg) | 0.000 ± 0.0000 |
| Day 4 (>=20 kg) | 0.000 ± 0.0000 |
| Day 6 (>=20 kg) | 0.000 ± 0.0000 |
Results provided by body-weight groups for participants in the Baloxavir Marboxil arm. Values below lower limit of quantification (0.5 ng/mL) are set to zero.
| ng/mL | Baloxavir Marboxil |
|---|---|
| Day 1, 0.5 - 2 hrs (10 - <15 kg) | 10.768 ± 14.7987 |
| Day 1, 4 hrs (10 - <15 kg) | 49.500 ± 13.0108 |
| Day 1, 6 hrs (10 - <15 kg) | 41.000 ± NA |
| Day 2 (10 - <15 kg) | 28.933 ± 14.7514 |
| Day 4 (10 - <15 kg) | 2.230 ± NA |
| Day 6 (10 - <15 kg) | 3.131 ± 2.2828 |
| Day 10 (10 - <15 kg ) | 0.000 ± NA |
| Day 1, 0.5 - 2 hrs (15 - <20 kg) | 93.883 ± 152.5431 |
| Day 1, 4 hrs (15 - <20 kg) | 72.900 ± NA |
| Day 1, 6 hrs (15 - <20 kg) | 80.300 ± NA |
| Day 2 (15 - <20 kg) | 42.640 ± 47.6024 |
| Day 4 (15 - <20 kg) | 12.200 ± NA |
| Day 6 (15 - <20 kg) | 2.663 ± 1.5387 |
| Day 1, 0.5 - 2 hrs (>=20 kg) | 19.923 ± 27.0980 |
| Day 1, 4 hrs (>=20 kg) | 69.198 ± 55.7220 |
| Day 1, 6 hrs ((>=20 kg) | 65.527 ± 43.0799 |
| Day 2 (>=20 kg) | 57.980 ± 37.8922 |
| Day 4 (>=20 kg) | 21.775 ± 3.7968 |
| Day 6 (>=20 kg) | 6.240 ± 3.3702 |
Time to alleviation of influenza signs and symptoms is defined as the length of time taken from the start of treatment to the point at which all of the following criteria are met and remain so for at least 21.5 hours: * A score of 0 (no problem) or 1 (minor problem) for cough and nasal symptoms (items 14 and 15 of the Canadian Acute Respiratory Illness and Flu Scale \[CARIFS\]) * A "yes" response to the following question on the CARIFS: "Since the last assessment has the subject been able to return to day care/school, or resume his or her normal daily activity in the same way as performed prior to developing the flu?" * First return to afebrile state (tympanic temperature ≤37.2 degree Celsius \[°C\])
| hours | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Time to Alleviation of Influenza Signs and Symptoms | 138.1 (116.6 to 163.2) | 150.0 (115.0 to 165.7) |
Length of time taken by participants to return to afebrile state \[tympanic temperature ≤ 37.2°C\] and remaining so for at least 21.5 hours.
| hours | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Duration of Fever | 41.2 (24.5 to 45.7) | 46.8 (30.0 to 53.5) |
The clinical efficacy of baloxavir marboxil is evaluated by duration of symptoms i.e., alleviation of all symptoms as defined by a score of 0 \[no problem\] or 1 \[minor problem\] and remaining so for at least 21.5 hours, for all 18 symptoms specified in the CARIFS questionnaire.
| hours | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Duration of Symptoms | 66.4 (43.7 to 76.4) | 67.9 (45.8 to 88.7) |
Time to Return to Normal health and activity' is identified by a 'Yes' response to the following question on the CARIFS: "Since the last assessment has the patient been able to return to day care/school, or resume his or her normal daily activity in the same way as performed prior to developing the flu?"
| hours | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Time to Return to Normal Health and Activity | 116.5 (94.9 to 138.0) | 111.6 (80.8 to 138.3) |
Influenza related complications include death, hospitalization, radiologically confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, myositis.
| count of events | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Total | 6 | 4 |
| Death | 0 | 0 |
| Hospitalization | 0 | 0 |
| Sinusitis | 1 | 0 |
| Otitis Media | 3 | 3 |
| Pneumonia | 1 | 0 |
| Bronchitis | 1 | 0 |
| Encephalitis/Encephalopathy | 0 | 0 |
| Febrile Seizures | 0 | 1 |
| Myositis | 0 | 0 |
Influenza related complications include death, hospitalization, radiologically confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, myositis.
| percentage of participants | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Total | 7.4 | 7.0 |
| Death | 0 | 0 |
| Hospitalization | 0 | 0 |
| Sinusitis | 1.2 | 0 |
| Otitis Media | 3.7 | 4.7 |
| Pneumonia | 1.2 | 0 |
| Bronchitis | 1.2 | 0 |
| Encephalitis/Encephalopathy | 0 | 0 |
| Febrile Seizures | 0 | 2.3 |
| Myositis | 0 | 0 |
| percentage of participants | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Total | 4.9 | 4.7 |
| Bronchitis | 0 | 0 |
| Otitis Media | 2.5 | 4.7 |
| Pneumonia | 1.2 | 0 |
| Sinusitis | 1.2 | 0 |
Time to cessation of viral shedding by virus titer is defined as the time, in hours, between the initiation of any study treatment and first time when the influenza virus titer is below the limit of detection.
| hours | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Time to Cessation of Viral Shedding by Virus Titer | 24.2 (23.5 to 24.6) | 75.8 (68.9 to 97.8) |
Time to cessation of viral shedding by RT-PCR, in hours, is defined as the time between the initiation of any study treatment and first time when the virus RNA by RT-PCR is below the limit of detection.
| hours | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Time to Cessation of Viral Shedding by RT-PCR | 242.5 (235.8 to 262.8) | 238.9 (214.0 to 286.7) |
Influenza virus titer (log10TCID50/ML) is the quantity of influenza virus in a given volume within the samples obtained from nasal swabs. If influenza virus titer was less than the lower limit of quantification, the virus titer was imputed as 0.749 (log10TCID50/mL). A lower value indicates lower viral titer.
| log10TCID50/ML | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Baseline | 4.43 ± 1.36 | 4.27 ± 1.48 |
| Day 2 | -3.59 ± 1.34 | -1.79 ± 1.54 |
| Day 3 (optional visit) | -2.83 ± 0.58 | -2.63 ± 0.88 |
| Day 4 | -3.53 ± 1.38 | -3.27 ± 1.54 |
| Day 6 | -3.55 ± 1.32 | -3.52 ± 1.50 |
| Day 10 | -3.66 ± 1.40 | -3.50 ± 1.42 |
| Day 15 (optional visit) | -3.75 ± 0.54 | -3.63 ± 1.45 |
| Day 29 | -3.50 ± 1.43 | -3.75 ± 1.19 |
If the amount of virus RNA was less than the lower limit of quantification, the amount of virus RNA was imputed as 2.18 for flu A and 2.93 for flu B (log10 virus particles/mL)
| log10 virus particles/mL | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Baseline | 6.46 ± 1.50 | 6.86 ± 1.02 |
| Day 2 | -1.74 ± 1.13 | -1.12 ± 1.12 |
| Day 3 (optional) | -1.78 ± 1.50 | -2.21 ± 0.94 |
| Day 4 | -2.40 ± 1.50 | -2.47 ± 1.35 |
| Day 6 | -2.73 ± 1.78 | -3.32 ± 1.27 |
| Day 10 | -3.55 ± 1.62 | -3.81 ± 1.19 |
| Day 15 (optional) | -1.24 ± 3.06 | -4.44 ± NA |
| Day 29 | 2.18 ± NA | — |
| percentage of participants | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Baseline | 100 | 100 |
| Day 2 | 15.6 | 75.7 |
| Day 3 (optional) | 33.3 | 50.0 |
| Day 4 | 26.2 | 29.0 |
| Day 6 | 12.7 | 5.7 |
| Day 10 | 1.6 | 0 |
| percentage of participants | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Baseline | 100 | 100 |
| Day 2 | 95.9 | 100 |
| Day 3 (optional) | 100 | 100 |
| Day 4 | 89.9 | 97.0 |
| Day 6 | 83.1 | 75.7 |
| Day 10 | 46.5 | 44.1 |
| Day 15 (optional) | 40.0 | 25.0 |
| Day 29 | 25.0 | 0 |
Area under the curve (AUC) in virus titer was calculated using the trapezoidal method.
| log₁₀[TCID₅₀/mL]*hours | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Area Under the Curve in Virus Titer | -863.81 ± 543.37 | -849.29 ± 684.43 |
AUC in virus RNA (RT-PCR) is defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 10. AUC is calculated using the trapezoidal method similar to AUC in virus titer.
| log₁₀ VPs/mL*hours | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| Area Under the Curve in the Amount of Virus RNA (RT-PCR) | -381.53 ± 338.53 | -353.31 ± 304.01 |
Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.
| ng.hr/mL | Baloxavir Marboxil |
|---|---|
| Non-Asian - 2 mg/kg | NA ± NA |
| Asian - 40 mg | NA ± NA |
| Non-Asian - 40 mg | NA ± NA |
Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.
| ng.hr/mL | Baloxavir Marboxil |
|---|---|
| Non-Asian - 2 mg/kg | 4050 ± 2080 |
| Asian - 40 mg | 6600 ± NA |
| Non-Asian - 40 mg | 4390 ± 2080 |
Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.
| ng/mL | Baloxavir Marboxil |
|---|---|
| Non-Asian - 2 mg/kg | NA ± NA |
| Asian - 40 mg | NA ± NA |
| Non-Asian - 40 mg | NA ± NA |
Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.
| ng/mL | Baloxavir Marboxil |
|---|---|
| Non-Asian - 2 mg/kg | 109 ± 55.3 |
| Asian - 40 mg | 110 ± NA |
| Non-Asian - 40 mg | 83.2 ± 36.5 |
Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.
| hours | Baloxavir Marboxil |
|---|---|
| Non-Asian - 2 mg/kg | NA ± NA |
| Asian - 40 mg | NA ± NA |
| Non-Asian - 40 mg | NA ± NA |
Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.
| hours | Baloxavir Marboxil |
|---|---|
| Non-Asian - 2 mg/kg | 4.12 ± 2.07 |
| Asian - 40 mg | 5.50 ± NA |
| Non-Asian - 40 mg | 5.55 ± 3.79 |
Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.
| ng/mL | Baloxavir Marboxil |
|---|---|
| 24 - Non-Asian - 2 mg/kg | NA ± NA |
| 24 - Asian - 40 mg | NA ± NA |
| 24 - Non-Asian - 40 mg | NA ± NA |
| 72 - Non-Asian - 2 mg/kg | NA ± NA |
| 72 - Asian - 40 mg | NA ± NA |
| 72 - Non-Asian - 40 mg | NA ± NA |
| 96 - Non-Asian - 2 mg/kg | NA ± NA |
| 96 - Asian - 40 mg | NA ± NA |
| 96 - Non-Asian - 40 mg | NA ± NA |
| 240 - Non-Asian - 2 mg/kg | NA ± NA |
| 240 - Asian - 40 mg | NA ± NA |
| 240 - Non-Asian - 40 mg | NA ± NA |
Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.
| ng/mL | Baloxavir Marboxil |
|---|---|
| 24 - Non-Asian - 2 mg/kg | 55.7 ± 28.1 |
| 24 - Asian - 40 mg | 75.2 ± NA |
| 24 - Non-Asian - 40 mg | 53.2 ± 22.4 |
| 72 - Non-Asian - 2 mg/kg | 13.2 ± 7.15 |
| 72 - Asian - 40 mg | 28.9 ± NA |
| 72 - Non-Asian - 40 mg | 17.90 ± 8.910 |
| 96 - Non-Asian - 2 mg/kg | 7.61 ± 4.400 |
| 96 - Asian - 40 mg | 19.0 ± NA |
| 96 - Non-Asian - 40 mg | 11.3 ± 6.160 |
| 240 - Non-Asian - 2 mg/kg | 0.989 ± 0.887 |
| 240 - Asian - 40 mg | 3.31 ± NA |
| 240 - Non-Asian - 40 mg | 1.85 ± 1.400 |
Collected over From baseline (Day 1) until 28 days after the last dose of study drug (29 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baloxavir Marboxil | 0/115 (0%) | 0/115 (0%) | 15/115 (13%) |
| Oseltamivir | 0/58 (0%) | 0/58 (0%) | 13/58 (22.4%) |
| Event | Baloxavir Marboxil | Oseltamivir |
|---|---|---|
| VomitingGastrointestinal disorders | 7/115 | 9/58 |
| Otitis MediaInfections and infestations | 3/115 | 4/58 |
| DiarrhoeaGastrointestinal disorders | 6/115 | 1/58 |
| Age, Continuous(years) | Baloxavir Marboxil | Oseltamivir | Total |
|---|---|---|---|
| Mean | 6.10 ± 2.90 | 6.02 ± 3.20 | 6.08 ± 3.00 |
| Sex: Female, Male(Participants) | Baloxavir Marboxil | Oseltamivir | Total |
|---|---|---|---|
| Female | 60 | 32 | 92 |
| Male | 55 | 26 | 81 |
| Race/Ethnicity, Customized(participants) | Baloxavir Marboxil | Oseltamivir | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 0 | 1 |
| Black or African American | 6 | 5 | 11 |
| Native Hawaiian or other Pacific Islander | 0 | 1 | 1 |
| White | 98 | 51 | 149 |
| Multiple | 4 | 0 | 4 |
| Unknown | 5 | 1 | 6 |
| Race/Ethnicity, Customized(participants) | Baloxavir Marboxil | Oseltamivir | Total |
|---|---|---|---|
| Hispanic or Latino | 52 | 27 | 79 |
| Not Hispanic or Latino | 63 | 31 | 94 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2018 to primary completion in Apr 2019, 4 months.
Results were first posted in Apr 2020, 1 year after primary completion.
Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 4 months is below that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baloxavir